PolyPeptide Group AG (PPGN)
Guardado en:
| Publicado en: | GlobalData Financial Profiles (2025) |
|---|---|
| Publicado: |
GlobalData plc
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Resumen: | PolyPeptide Group AG (PPGN) - Financial Analysis Review PolyPeptide Group AG (PolyPeptide) is a contract development and manufacturing organization (CDMO) that develops and commercializes generic GMP-grade peptides and peptide-related molecules. The company offers generic peptides, custom research grade peptides, cosmetic peptides. PolyPeptide products find application in various therapeutic areas such as endocrinology, musculoskeletal, pediatrics, gynecology, oncology, urology and others. GlobalData's PolyPeptide Group AG (PPGN) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years. PolyPeptide Group AG Key Recent Developments: Jan 13,2025: Cytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs Jan 08,2025: Doubling of Production Capacity at the Manufacturing Site in Malmo Dec 16,2024: Large-Scale SPPS Capacity in Braine-l’Alleud Starts Production Apr 10,2024: PolyPeptide announces results of the annual General Meeting 2024 This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. |
|---|---|
| Fuente: | ABI/INFORM Trade & Industry |